Download MendeleySU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2.
Moshinsky, D.J., Bellamacina, C.R., Boisvert, D.C., Huang, P., Hui, T., Jancarik, J., Kim, S.H., Rice, A.G.(2003) Biochem Biophys Res Commun 310: 1026-1031
- PubMed: 14550307
- DOI: https://doi.org/10.1016/j.bbrc.2003.09.114
- Primary Citation of Related Structures:
1PF8 - PubMed Abstract:
SU9516 is a 3-substituted indolinone compound with demonstrated potent and selective inhibition toward cyclin dependent kinases (cdks). Here, we describe the kinetic characterization of this inhibition with respect to cdk2, 1, and 4, along with the crystal structure in complex with cdk2. The molecule is competitive with respect to ATP for cdk2/cyclin A, with a K(i) value of 0.031 microM. Similarly, SU9516 inhibits cdk2/cyclin E and cdk1/cyclin B1 in an ATP-competitive manner, although at a 2- to 8-fold reduced potency. In contrast, the compound exhibited non-competitive inhibition with respect to ATP toward cdk4/cyclin D1, with a 45-fold reduced potency. The X-ray crystal structure of SU9516 bound to cdk2 revealed interactions between the molecule and Leu83 and Glu81 of the kinase. This study should aid in the development of more potent and selective cdk inhibitors for potential therapeutic agents.
Organizational Affiliation:
SUGEN, Inc., South San Francisco, CA 94080, USA. deborah.moshinsky@pharma.novartis.com
